News

Activation Capital Names New Vice President for Operations

Activation Capital, an innovation ecosystem development organization, announced that it has appointed Kipton Currier as its Vice President of Operations. The new role comes as the organization clarifies its strategic direction, begins raising growth capital, and adopts a fresh operational approach to its mission. Currier will help build infrastructure across multiple organizational areas, including people, policies, space-making, and systems, to improve performance and help achieve ambitious goals for the regional innovation ecosystem.

“Activation Capital, with its Board, has been redesigning the organization and is now better positioned to drive transformational change. We are delighted to add Kipton Currier to the team as we continue to build a unique ecosystem that unlocks entrepreneurship, scales strong companies, and transforms communities,” said Chandra Briggman, president, and CEO of Activation Capital. “Kipton is a high-impact professional with a unique set of skills at the intersection of health and life sciences, entrepreneurship, and real estate that is critical at this stage in our evolution.”

As a social impact executive, Currier has dedicated her career to serving missions for the greater good. After a successful career in Manhattan real estate, Currier has worked in finance, healthcare, and life sciences. Originally from the tri-city area, Currier moved back to the Richmond region five years ago and has since helped launched three major initiatives, including a health data analytics firm, a national philanthropic guarantee bank, and, most recently, a pharmaceutical manufacturer. Currier has an undergraduate degree from the University of Virginia and a Master of Business Administration from the College of William and Mary.

“As a fourth-generation Virginia entrepreneur, I was drawn to Activation Capital’s vision, mission, and values, and its role in catalyzing entrepreneurship in the region,” said Currier. “I look forward to helping the organization operationalize its strategy. Activation Capital has tremendous opportunity for a bigger, bolder future. I am eager to contribute to its growth and work with the team and partners in these endeavors.”

The appointment comes on the heels of recent wins for the organization, including leading the efforts to secure a $55.9M Build Back Better Regional Challenge award for the region, and a $450K GO Virginia Region 4 Grant to design a regional entrepreneurship strategy. Currier will begin her role as Vice President of Operations at Activation Capital on December 6, 2022.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation